# Chai Discovery

> AI molecular-design company licensing research models and tools to pharmaceutical teams.

## Why it is interesting

A July 2026 $400M Series C coincided with a growing list of named pharma collaborations; commercial renewals and demonstrated experimental outcomes matter more than announced partnership counts.

## Profile

- **Latest funding:** Series C — $400M (July 14, 2026)
- **Latest known valuation:** $3.8B valuation (company announcement; valuation basis not specified) (July 14, 2026)
- **Total disclosed equity funding:** $400M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension

## Funding history

- Series C · $400M · July 14, 2026
  Source: https://www.chaidiscovery.com/news/series-c

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/chai-discovery